Prednisone

别名: Prednisone; Dehydrocortisone; Deltasone; Meticorten; Decortin; Prednisonum; Deltasone; Encorton; Encortone; Enkortolon 泼尼松; 17Α,21-二羟基-1,4-孕甾二烯-3,11,20-三酮; 脱氢可的松;强的松; 去氢可的松; 170,21-二羟基-Δ1,4-孕甾二烯-3,11,20-三酮, 17Α,21-DIHYDROXY-1,4-PREGNADIENE-3,11,20-TRIONE;泼尼松,PREDNISONE;去氢皮质素;泼尼松原粉
目录号: V1699 纯度: ≥98%
泼尼松(也称为脱氢可的松;商品名:Adasone、Deltasone、Liquid Pred、Orasone 等)是一种经批准的糖皮质激素药物,主要用于抑制免疫系统并减少哮喘、慢性阻塞性肺病和风湿病等疾病的炎症。
Prednisone CAS号: 53-03-2
产品类别: Calcium Channel
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
500mg
1g
2g
5g
10g
50g
Other Sizes

Other Forms of Prednisone:

  • Prednisone-d8 (Dehydrocortisone-d8)
  • Prednisone acetate-d3 (Prednisone 21-acetate-d3)
  • 醋酸泼尼松
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
泼尼松(也称为脱氢可的松;商品名:Adasone、Deltasone、Liquid Pred、Orasone 等)是一种经批准的糖皮质激素药物,主要用于抑制免疫系统并减少哮喘、慢性阻塞性肺病和风湿病等疾病的炎症。泼尼松是一种有效的合成皮质类固醇药物,作为免疫抑制剂化合物特别有效。它用于治疗某些炎症性疾病,例如中度过敏反应、一些自身免疫性疾病和某些类型的癌症,但它有显着的副作用。泼尼松可降低粘膜 TNF-a 的产生、肠道通透性和 NF-κB 表达水平。
生物活性&实验参考方法
体外研究 (In Vitro)
体外活性:泼尼松可阻断细胞周期 G1 期的外周血淋巴细胞 (PBL) 生长,并抑制活化的人外周血 T 淋巴细胞中的 IL-2 受体 (IL-2R) 表达和 IL-2 分泌。泼尼松可增加 PHA 激活的人 PBL 的凋亡,且泼尼松对 CD8(+) T 淋巴细胞的凋亡作用强于对 CD4(+) T 淋巴细胞。
体内研究 (In Vivo)
与对照组相比,泼尼松(肌肉注射,10 mg/kg,每日一次,第 4-13 天)降低了患有脑心肌炎病毒性心肌炎的 BALB/c 小鼠的存活率。此外,心肌病毒滴度在第4天达到峰值,但不存在抗体滴度。第8天,病毒和抗体滴度仍然升高。与对照相比,第 10 天抗体滴度仍显着升高,但病毒滴度显着降低[2]。在SLE小鼠(MRL/lpr)模型中,泼尼松(5 mg/kg,胃内给药,每日一次)可以改变FA的代谢[3]。
动物实验
Animal/Disease Models: Female MRL/lpr mice[3]
Doses: 5 mg/kg
Route of Administration: intragastrically (po) administration, daily
Experimental Results: Elevated polyunsaturated FA, such as arachidonic acid and docosahexaenoic acid, and decreased the total level of n-6 polyunsaturated fatty acids in.
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
Oral prednisone has a Tmax of 2 hours, while the delayed-release formulation has a Tmax of 6-6.5 hours. A 5mg dose of prednisone has an AUC of 572mL/min/1.73m2, a 20mg dose of prednisone has an AUC of 1034mL/min/1.73m2, and a 50mg dose of prednisone has an AUC of 2271mL/min/1.73m2. Data regarding the Cmax of prednisone is not readily available.
Prednisone is excreted mainly in the urine as sulfate and glucuronide conjugates.
Data regarding the volume of distribution for prednisone is not readily available. However, a 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.
Data regarding the clearance of prednisone is not readily available. A 5.5µg/h/kg infusion of prednisolone has an average clearance of 0.066±0.12L/h/kg, while a 0.15±0.03L/h/kg infusion has an average clearance of 0.15L/h/kg.
Thirty minutes after iv administration of (3)H-prednisone to a monkey, the concentration of prednisone was highest in the kidney. The drug was also found in the liver, spleen, lung, small intestine, serum and bile. The concentration of prednisolone was highest in the liver. It was also found in the kidney, pancreas, spleen, lung, small intestine, serum and bile.
Prednisone is readily absorbed from the gut. Serum concentrations of prednisone and prednisolone, its active metabolite, have been found to be maximal 1 hour after oral administration of a 5-mg tablet of prednisone to beagle dogs. Following both ip and oral administration of prednisone to mice, serum levels of prednisone, prednisolone and other metabolites were maximal at 15 min. These levels were higher in mice given ip injections of prednisone than in those receiving the same doses by the oral route. Oral administration of prednisone to dogs and monkeys led to serum levels comparable with those following iv injections, but individual variations were relatively large.
Prednisone is readily absorbed from the gut. In a series of 22 normal subjects, the mean peak serum concentration was 930 ug/L (range, 508-1579) following oral administration of a 50 mg tablet.
The protein binding characteristics of prednisone and prednisolone, alone and together, in human and rabbit plasma and human serum albumin, are reported. The kinetics of prednisolone binding were nonlinear and those of prednisone were linear in both human and rabbit plasma; prednisone binding was linear with human serum albumin, although to a lesser degree. It is suggested that prednisone binds to proteins other than albumin in plasma. Binding of prednisone was not influenced by prednisolone. The results support the hypothesis that the protein binding characteristics of prednisone and prednisolone do not explain the reported nonlinear pharmacokinetics of prednisone.
Administration of physiologic doses unlikely to adversely affect infant. FDA Category: C (C = Studies in laboratory animals have revealed adverse effects on the fetus (teratogenic, embryocidal, etc.) but there are no controlled studies in pregnant women. The benefits from use of the drug in pregnant women may be acceptable despite its potential risks, or there are no laboratory animal studies or adequate studies in pregnant women.) /Adrenocorticosteroids/ /from table II/
Metabolism / Metabolites
Prednisone is metabolized to 17α,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20α-dihydro-prednisone (M-V), 6βhydroxy-prednisone (M-XII), 6α-hydroxy-prednisone (M-XIII), or 20β-dihydro-prednisone (M-IV). 20β-dihydro-prednisone is metabolized to 17α,20ξ,21-trihydroxy-5ξ-pregn-1-en-3,11-dione(M-XVIII). Prednison is reversibly metabolized to [prednisolone]. Prednisolone is metabolized to Δ6-prednisolone (M-XI), 20α-dihydro-prednisolone (M-III), 20β-dihydro-prednisolone (M-II), 6αhydroxy-prednisolone (M-VII), or 6βhydroxy-prednisolone(M-VI). 6αhydroxy-prednisolone is metabolized to 6α,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-X). 6βhydroxy-prednisolone is metabolized to 6β,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6β,11β,17α,20α,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6β,11β,17α,21-tetrahydroxy-5ξ-pregn-1-en-3,20-dione (M-XIV). MVIII is metabolized to 6β,11β,17α,20β,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6β,11β,17α,20α,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XVI) and then to MXIV. These metabolites and their glucuronide conjugates are excreted predominantly in the urine.
In one study after an oral dose of prednisone, the plasma prednisolone concentration peaked between 60 and 120 min and then declined exponentially. After rapid iv injection of steroid, the plasma prednisolone concentration peaked within 10 to 20 min. An initial rapid distribution phase succeeded by a slower decay phase was expressed by a biphasic exponential disappearance curve of the plasma prednisolone concentration versus time. Plasma prednisolone concentrations achieved with an oral dose of prednisone were in the same range as those obtained during the second phase after iv administration.
Reduction of the 11-oxo to the 11alpha-hydroxyl group by the enzyme 11beta-hydroxydehydrogenase converts prednisone to prednisolone, its biologically active form. This reaction takes place mainly in the liver, and may proceed satisfactorily even in the presence of liver disease
In vitro, prednisone is converted to prednisolone by liver, lung and renal tissue. Conversely, prednisolone is converted to prednisone by renal tissue.
... The aim of this work was to evaluate the effects of these corticosteroids on the expression of several forms of cytochromes p450, including p450 1A2, 2D6, 2E1, and 3A, and on cyclosporin A oxidase activity in human liver. For this purpose, human hepatocytes prepared from lobectomies were maintained in culture in a serum-free medium, in collagen-coated dishes, for 96-144 hr, in the absence or presence of 50-100 uM corticosteroids, rifampicin, or dexamethasone. To mimic more closely the current clinical protocol, hepatocyte cultures were also co-treated with corticosteroids and cyclosporin A or ketoconazole (a selective inhibitor of cytochromes p450 3A). Cyclosporin A oxidase activity, intracellular retention of cyclosporin A oxidized metabolites within hepatocytes, accumulation of cytochromes p450 proteins and corresponding messages, and de novo synthesis and half-lives of these cytochromes p450 were measured in parallel in these cultures. Our results, obtained from seven different hepatocyte cultures, showed that 1) dexamethasone and prednisone, but not prednisolone or methylprednisolone, were inducers of cytochrome p450 3A, at the level of protein and mRNA accumulation, as well as of cyclosporin A oxidase activity, known to be predominantly catalyzed by these cytochromes p450; 2) although corticosteroids are known to be metabolized in human liver, notably by cytochrome p450 3A, partial or total inhibition of this cytochromes p450 by cyclosporin or ketoconazole, respectively, did not affect the inducing efficiency of these molecules; 3) corticosteroids did not affect the half-life of cytochrome p450 3A or the accumulation of other forms of cytochromes p450, including 1A2, 2D6, and 2E1; 4) chronic treatment of cells with cyclosporin did not affect cytochrome p450 3A accumulation; 5) corticosteroids were all competitive inhibitors of cyclosporin A oxidase in human liver microsomes, with Ki values of 61 + or - 12, 125 + or - 25, 190 + or - 38, and 210 + or - 42 uM for dexamethasone, prednisolone, prednisone, and methylprednisolone, respectively; and 6) chronic treatment of cells with corticosteroids did not influence the excretion of oxidized metabolites of cyclosporin from the cells.
Prednisone is completely converted to the active metabolite prednisolone by 11‘_-hydroxysteroid dehydrogenases. It is then further metabolized mainly in the liver. The exposure of prednisolone is 4-6 fold higher than that of prednisone.
Route of Elimination: Excreted in the urine as sulfate and glucuronide conjugates.
Half Life: Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.
Biological Half-Life
Prednisone and its active metabolite [prednisolone] have half lives of 2-3 hours from both immediate and delayed release preparations.
In a series of 22 normal subjects, the mean peak serum concentration was 930 ug/L (range, 508-1579) following oral administration of a 50 mg tablet. The overall mean serum half-life was 2.95 hours
毒性/毒理 (Toxicokinetics/TK)
Toxicity Summary
IDENTIFICATION AND USE: Prednisone is white crystalline powder with a persistent bitter after-taste. It is glucocorticoid, anti-inflammatory agent and antineoplastic agent. HUMAN EXPOSURE AND TOXICITY: Prednisone causes profound and varied metabolic effects when used at therapeutic doses, given on a continuous basis. When given in large doses it can induce cardiac complications. In addition, it modifies the body's immune response to diverse stimuli; among the changes that occur are lymphopenia, monocytopenia and suppression of delayed hypersensitivity skin tests. Fluid and electrolyte disturbances may occur, including sodium and fluid retention, which may lead to congestive heart failure and hypertension. With large doses, potassium loss, hypokalemic alkalosis, and increased calcium excretion may occur. Glucocorticoids may cause fetal damage when administered to pregnant women. One retrospective study of 260 women who received pharmacologic dosages of glucocorticoids during pregnancy revealed 2 instances of cleft palate, 8 stillbirths, 1 spontaneous abortion, and 15 premature births. Another study reported 2 cases of cleft palate in 86 births. No chromosomal damage was detected in peripheral lymphocytes of patients treated with 3 mg/kg bw per day prednisone alone for 28 days and then with 0.5-1 mg/kg bw per day for 18-120 months. ANIMAL STUDIES: Carcinogenicity studies have been conducted in rats and mice. Of treated males, 7/20 developed tumors, among which were 3 pituitary tumors and 1 tumor of the breast; 16/18 female rats developed tumors, 8 of the breast, 5 of the pituitary, 2 of the adrenal and 1 of the liver. The overall tumor incidence in females was 1.5-2-fold higher than that in controls. However in mice, the tumor incidence in treated males was 4/19 (21%), with 2 lymphosarcomas and 2 lung tumors, and that in treated females was 8/27 (30%), with 4 lung tumors, 2 lymphosarcomas and 2 uterine tumors. These incidences were not significantly greater than those in controls. Prednisone given to rats from the 11th day of pregnancy until parturition at daily doses of 2.5 or 5 mg was reported to inhibit the growth of the fetal thymus and spleen. Prednisone was not mutagenic in Escherichia coli, and it caused no chromosomal damage when administered to rats. ECOTOXICITY STUDIES: The rotifer Brachionus calyciflorus and two crustaceans, the cladoceran Daphnia magna and the anostracan Thamnocephalus platyurus, were used to perform acute toxicity tests. Chronic toxicity tests have been performed on the alga Pseudokirchneriella subcapitata and the crustacean Ceriodaphnia dubia. The results showed low acute and chronic toxicity of prednisone. Some of the photoproducts had high toxic effects on C. dubia.
Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Amounts of prednisone in breastmilk are very low. No adverse effect have been reported in breastfed infants with maternal use of any corticosteroid during breastfeeding. Although it is often recommended to avoid breastfeeding for 4 hours after a dose this maneuver is not necessary because prednisone milk levels are very low. Medium to large doses of corticosteroids given systemically or injected into joints or the breast have been reported to cause temporary reduction of lactation.
◉ Effects in Breastfed Infants
None reported with prednisone or any other corticosteroid. In a prospective follow-up study, six nursing mothers reported taking prednisone (dosage unspecified) with no adverse infant effects.
There are several reports of mothers breastfeeding during long-term use of corticosteroids with no adverse infant effects: prednisone 10 mg daily (2 infants) and prednisolone 5 to 7.5 mg daily (14 infants).
A woman with Crohn's disease used prednisone 60 mg daily in a tapering schedule immediately postpartum during breastfeeding (extent not stated). She also received sulfasalazine 4 grams daily and infliximab 5 mg/kg every 8 weeks during pregnancy and postpartum. At 6 months of age, the infant was asymptomatic with regular weight gain.
The National Transplantation Pregnancy Registry reports that as of December 2013, 124 women with transplants have taken prednisone while breastfeeding 169 infants for periods as long as 48 months, with no apparent infant harm.
◉ Effects on Lactation and Breastmilk
Published information on the effects of prednisone on serum prolactin or on lactation in nursing mothers was not found as of the revision date. Medium to large doses of corticosteroids given systemically or injected into joints or the breast have been reported to cause temporary reduction of lactation.
A study of 46 women who delivered an infant before 34 weeks of gestation found that a course of another corticosteroid (betamethasone, 2 intramuscular injections of 11.4 mg of betamethasone 24 hours apart) given between 3 and 9 days before delivery resulted in delayed lactogenesis II and lower average milk volumes during the 10 days after delivery. Milk volume was not affected if the infant was delivered less than 3 days or more than 10 days after the mother received the corticosteroid. An equivalent dosage regimen of prednisone might have the same effect.
A study of 87 pregnant women found that betamethasone given as above during pregnancy caused a premature stimulation of lactose secretion during pregnancy. Although the increase was statistically significant, the clinical importance appears to be minimal. An equivalent dosage regimen of prednisone might have the same effect.
Protein Binding
Corticosteroids are generally bound to corticosteroid binding globulin and serum albumin in plasma. Prednisone is <50% bound to protein in plasma.
Interactions
Concomitant use of anticholinesterase agents (e.g., neostigmine, pyridostigmine) and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. If concomitant therapy must occur, it should take place under close supervision and the need for respiratory support should be anticipated. /Corticosteroids/
Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. /Corticosteroids/
Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. /Corticosteroids/
Cholestyramine may increase the clearance of corticosteroids. /Corticosteroids/
For more Interactions (Complete) data for PREDNISONE (25 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Mouse im 600 mg/kg
LD50 Mouse sc 101 mg/kg
LD50 Mouse ip 135 mg/kg
参考文献
[1]. RIEMER AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. Am J Cardiol. 1958 Apr;1(4):488-96.
[2]. [2]N Tomioka, et al. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol. 1986 Apr;7(4):868-72.
[3]. Qianqian Li, et al. Metabolic Profiling Reveals an Abnormal Pattern of Serum Fatty Acids in MRL/lpr Mice Under Treatment With Prednisone. Front Pharmacol. 2020 Feb 25;11:115.
其他信息
Therapeutic Uses
Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Glucocorticoids
Prednisone is usually considered the oral glucocorticoid of choice for anti-inflammatory or immunosuppressant effects. Because it has only minimal mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If prednisone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.
Prednisone tablets and solutions are indicated in the following conditions: Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. /Included in US product label/
Prednisone tablets and solutions are indicated in the following conditions: Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. /Included in US product label/
For more Therapeutic Uses (Complete) data for PREDNISONE (19 total), please visit the HSDB record page.
Drug Warnings
The profound effects of prednisone on the immune system place patients at increased risk of developing infections of various types. Prednisone may mask some of the signs of infection, and may decrease host resistance and interfere with the ability to localize infections. During prednisone therapy, a polymorphonuclear leukocytosis may develop and may give rise to confusion in the diagnosis of infection. This elevation is dose-related.
Psychiatric reactions have been reported in 4-36% of patients. These disturbances may take various forms, for example, insomnia, changes in mood or psyche, and psychopathies of the manic-depressive or schizophrenic type.
Ophthalmic complications include the development of posterior subcapsular cataracts, and increased intraocular pressure which may lead to glaucoma. In patients with ocular herpes simplex, it may cause corneal perforation.
There are numerous endocrine side effects. Most frequent is development of the Cushingoid state. Fatty deposits in the mediastinum causing mediastinal widening may simulate mediastinal lymphadenopathy. Menstrual irregularities, including amenorrhoea, may occur. There may be secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness. The processes of recovery of normal pituitary and adrenal function require about 1 year in some patients. There may be stunted growth and delayed skeletal maturation in children. Prednisone causes decreased carbohydrate tolerance and may unmask the features of latent diabetes.
For more Drug Warnings (Complete) data for PREDNISONE (38 total), please visit the HSDB record page.
Pharmacodynamics
Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisone has a short duration of action as the half life is 2-3 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C21H26O5
分子量
358.43
精确质量
358.178
CAS号
53-03-2
相关CAS号
Prednisone-d8;Prednisone acetate;125-10-0
PubChem CID
5865
外观&性状
Crystals
White to practically white, crystalline powder
密度
1.3±0.1 g/cm3
沸点
573.7±50.0 °C at 760 mmHg
熔点
236-238 °C(lit.)
闪点
314.8±26.6 °C
蒸汽压
0.0±3.6 mmHg at 25°C
折射率
1.604
LogP
1.57
tPSA
91.67
氢键供体(HBD)数目
2
氢键受体(HBA)数目
5
可旋转键数目(RBC)
2
重原子数目
26
分子复杂度/Complexity
764
定义原子立体中心数目
6
SMILES
O([H])[C@]1(C(C([H])([H])O[H])=O)C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])=C([H])[C@]4(C([H])([H])[H])[C@@]3([H])C(C([H])([H])[C@@]21C([H])([H])[H])=O)=O
InChi Key
XOFYZVNMUHMLCC-ZPOLXVRWSA-N
InChi Code
InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
化学名
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
别名
Prednisone; Dehydrocortisone; Deltasone; Meticorten; Decortin; Prednisonum; Deltasone; Encorton; Encortone; Enkortolon
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO: 71 mg/mL (198.1 mM)
Water:<1 mg/mL
Ethanol:<1 mg/mL
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.08 mg/mL (5.80 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 20.8 mg/mL澄清DMSO储备液加入400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 2 中的溶解度: ≥ 2.08 mg/mL (5.80 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 20.8 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。
*20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。

View More

配方 3 中的溶解度: ≥ 2.08 mg/mL (5.80 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 20.8 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。


请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 2.7899 mL 13.9497 mL 27.8995 mL
5 mM 0.5580 mL 2.7899 mL 5.5799 mL
10 mM 0.2790 mL 1.3950 mL 2.7899 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
CTID: NCT02861573
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-12-02
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
CTID: NCT06353386
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-12-02
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
CTID: NCT06136624
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
CTID: NCT05039619
Phase: Phase 2    Status: Recruiting
Date: 2024-12-02
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
CTID: NCT05675410
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
View More

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
CTID: NCT03223610
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-12-02


A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
CTID: NCT04980222
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-12-02
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
CTID: NCT04759586
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
CTID: NCT01786265
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
CTID: NCT03436654
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
CTID: NCT02703623
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
CTID: NCT04662580
Phase: Phase 1    Status: Recruiting
Date: 2024-11-29
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
CTID: NCT02723994
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-29
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
CTID: NCT03511196
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-11-29
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
CTID: NCT05389423
Phase: Phase 1    Status: Suspended
Date: 2024-11-27
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
CTID: NCT03952637
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-27
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
CTID: NCT04799275
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-11-27
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
CTID: NCT06704555
Phase: Phase 2    Status: Recruiting
Date: 2024-11-26
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
CTID: NCT06378866
Phase: Phase 2    Status: Recruiting
Date: 2024-11-26
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
CTID: NCT03117751
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-26
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
CTID: NCT06047080
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
CTID: NCT00092222
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
CTID: NCT04446117
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-25
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
CTID: NCT04633252
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-25
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
CTID: NCT05371054
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-25
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
CTID: NCT04530565
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
CTID: NCT04739813
Phase: Phase 1    Status: Recruiting
Date: 2024-11-25
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
CTID: NCT03860987
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
CTID: NCT05371093
Phase: Phase 3    Status: Recruiting
Date: 2024-11-22
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial
CTID: NCT06700798
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-22
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
CTID: NCT02406092
Phase: Phase 3    Status: Completed
Date: 2024-11-21
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
CTID: NCT01920932
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-21
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
CTID: NCT06356129
Phase: Phase 3    Status: Recruiting
Date: 2024-11-21
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
CTID: NCT02877303
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
CTID: NCT05008224
Phase: Phase 2    Status: Completed
Date: 2024-11-20
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
CTID: NCT05455697
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-20
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
CTID: NCT06425302
Phase: Phase 2    Status: Recruiting
Date: 2024-11-19
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
CTID: NCT06624670
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-11-19
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
CTID: NCT06692452
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-18
Prednisone for CRPS in Distal Radius Fracture
CTID: NCT06453447
Phase: N/A    Status: Recruiting
Date: 2024-11-18
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
CTID: NCT06143891
Phase: Phase 3    Status: Recruiting
Date: 2024-11-15
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
CTID: NCT06633419
Phase: Phase 1    Status: Recruiting
Date: 2024-11-15
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
CTID: NCT04477512
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
CTID: NCT00792948
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
CTID: NCT02166463
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
CTID: NCT02883049
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
CTID: NCT01856192
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
CTID: NCT02960022
Phase: Phase 2    Status: Recruiting
Date: 2024-11-13
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
CTID: NCT00602641
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
SHR0302 and Steroid As First Line Therapy for Chronic GVHD
CTID: NCT04146207
PhaseEarly Phase 1    Status: Completed
Date: 2024-11-13
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
CTID: NCT00972478
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
CTID: NCT03269669
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-12
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
CTID: NCT05457257
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-11-12
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
CTID: NCT03984448
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-12
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
CTID: NCT02784210
Phase: Phase 2    Status: Recruiting
Date: 2024-11-12
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
CTID: NCT03220022
Phase: Phase 1    Status: Recruiting
Date: 2024-11-12
Study of Relugolix in Men with Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
CTID: NCT04666129
Phase: Phase 1    Status: Completed
Date: 2024-11-08
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
CTID: NCT03414034
Phase: Phase 2    Status: Completed
Date: 2024-11-07
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
CTID: NCT06676579
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-06
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
CTID: NCT04729114
Phase: Phase 1    Status: Recruiting
Date: 2024-11-06
Twice Weekly Steroids and Exercise as Therapy for DMD
CTID: NCT04322357
Phase: Phase 2    Status: Recruiting
Date: 2024-11-06
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated with Antibody Therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy
CTID: NCT04745949
Phase: Phase 2    Status: Recruiting
Date: 2024-11-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
CTID: NCT05201248
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-05
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
CTID: NCT05605899
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
Intratympanic Steroid for Bell's Palsy
CTID: NCT03508440
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-11-05
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
CTID: NCT06191744
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
CTID: NCT05283720
Phase: Phase 2    Status: Recruiting
Date: 2024-11-05
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients with DLBCL
CTID: NCT04594798
Phase: Phase 2    Status: Recruiting
Date: 2024-11-05
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
CTID: NCT03749018
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-04
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
CTID: NCT04151082
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
CTID: NCT03419234
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-01
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
CTID: NCT02457221
Phase: Phase 3    Status: Completed
Date: 2024-11-01
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
CTID: NCT06470243
Phase: Phase 3    Status: Recruiting
Date: 2024-11-01
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma
CTID: NCT06043323
Phase: Phase 2    Status: Recruiting
Date: 2024-11-01
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
CTID: NCT04679012
Phase: Phase 2    Status: Recruiting
Date: 2024-10-31
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
CTID: NCT03589326
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-31
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
CTID: NCT04300556
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-31
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
CTID: NCT04850495
Phase: Phase 1    Status: Recruiting
Date: 2024-10-31
Belatacept in Heart Transplantation
CTID: NCT06478017
Phase: Phase 2    Status: Recruiting
Date: 2024-10-31
Short-term Glucocorticoid Combined with MMF for IgG4-RD
CTID: NCT06663618
Phase: N/A    Status: Recruiting
Date: 2024-10-29
Ruxolitinib Vs Prednisone As First-line Therapy for CGVHD Needing Systemic Therapy
CTID: NCT06660355
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-28
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
CTID: NCT04884035
Phase: Phase 1    Status: Recruiting
Date: 2024-10-26
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
CTID: NCT05157971
Phase: Phase 1    Status: Recruiting
Date: 2024-10-26
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
CTID: NCT04497844
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-24
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
CTID: NCT06656962
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-24
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
CTID: NCT03748641
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-24
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
CTID: NCT05811351
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-24
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
CTID: NCT02143414
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-23
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
CTID: NCT06566989
Phase: Phase 1    Status: Completed
Date: 2024-10-23
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
CTID: NCT06650579
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-23
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
CTID: NCT03467373
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-22
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
CTID: NCT05761171
Phase: Phase 2    Status: Recruiting
Date: 2024-10-22
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
CTID: NCT05032183
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-22
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
CTID: NCT06649812
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-21
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
CTID: NCT03914625
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
CTID: NCT02257736
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
CTID: NCT00408005
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-21
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
CTID: NCT03706365
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-10-18
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
CTID: NCT02911142
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-18
PK and Dose Escalation and Expansion Study of DST-2970
CTID: NCT04291664
Phase: Phase 1    Status: Terminated
Date: 2024-10-17
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
CTID: NCT06498089
Phase: Phase 4    Status: Recruiting
Date: 2024-10-17
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
CTID: NCT03816332
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-17
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
CTID: NCT05302271
Phase: Phase 1    Status: Recruiting
Date: 2024-10-17
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
CTID: NCT05848011
Phase: Phase 2    Status: Recruiting
Date: 2024-10-17
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
CTID: NCT04139304
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-10-16
Treatment With Prednisone of Women With RPL or RIF Positive to Antithyroid Antibodies and Embryotoxicity Test
CTID: NCT06641440
Phase: Phase 4    Status: Completed
Date: 2024-10-16
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
CTID: NCT05406401
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-15
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
CTID: NCT06317662
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-15
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
CTID: NCT03255473
Phase: Phase 2    Status: Withdrawn
Date: 2024-10-15
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
CTID: NCT06284122
Phase: Phase 3    Status: Recruiting
Date: 2024-10-15
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
CTID: NCT06554639
Phase: Phase 1    Status: Completed
Date: 2024-10-15
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
CTID: NCT03338790
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-15
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
CTID: NCT05681481
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-15
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
CTID: NCT05896839
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-15
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
CTID: NCT05267600
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-10-15
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
CTID: NCT04569032
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-15
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
CTID: NCT06037811
Phase: Phase 2    Status: Recruiting
Date: 2024-10-15
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
CTID: NCT04221477
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-15
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
CTID: NCT06635720
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-10
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
CTID: NCT03431350
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-10
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
CTID: NCT06124157
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-10
Comparing Immune System Suppression to Medication for Unexplained Heart Function and Irregular Heartbeat
CTID: NCT06635863
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-10-10
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
CTID: NCT02123758
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-09
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
CTID: NCT06533098
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-09
Treg Modulation With CD28 and IL-6 Receptor Antagonists
CTID: NCT04066114
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-10-09
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
CTID: NCT04577833
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-09
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
CTID: NCT02195479
Phase: Phase 3    Status: Completed
Date: 2024-10-08
-----------------------lse if(down_display === 'none' || down_display ===

相关产品
联系我们